drugset
drugset / Trial / NCT03934736

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736 ↗

Phase 1 Completed 119 enrolled Dynavax Technologies Corporation
NaSingle-groupOpen-labelPrevention

Summary

This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.

Timeline

Start
2019-04-22
Primary completion
2020-10-23
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject HEPLISAV-B Vaccine 0.5 ml Intramuscular

Indications

end stage renal failure